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The Microsimulation Model in Cancer of the Bowel (MiMiC-Bowel) incorporates individual cancer 
risk to inform colorectal cancer (CRC) screening decisions in England. This work reports calibration 
and cross-validation of the MiMiC-Bowel.  
Due to the complex and computationally intensive nature of the model a step-wise calibration 
approach was taken utilising manual and automated algorithmic fitting. Natural history disease model 
parameters were estimated via calibration to several data targets including English and adjusted 
German data relating to previously unscreened persons. The model was cross-validated to four 
international models.  
Incompatibility in calibration data was assessed by analysing CRC incidence, convergence feasibility, 
and predictions of screening test sensitivity. Data incompatibility was addressed by giving less weight 
in fitting the parameters to target data with lower reliability and applicability, and adjusting data sets 
to reflect differences between localities. The MiMiC-Bowel predicted 60% sensitivity of flexible 
sigmoidoscopy for CRC and 59% for high-risk adenoma. MiMiC-Bowel’s predictions of CRC cases 
that arise from potentially detectable adenomas and impact of perfect polypectomy on risk reduction 
were within ranges reported by the US models, but the predictions of the sojourn and dwell time were 
not (29.1 and 5.3 years vs 8-24 and 2-4 years respectively). CRC risk increased less rapidly by age in 
MiMiC-Bowel than German data suggests, which is supported by population data on pre-screening 




1. Brief description of the MiMiC-Bowel model 
The Microsimulation Model in Cancer of the Bowel (MiMiC-Bowel) is a patient-level 
microsimulation model in R programming language which was developed to simulate the 
development of colorectal cancer (CRC) over patients’ lifetime for the population of England. The 
model incorporates individual cancer risk and was populated with population characteristics retrieved 
from the Health Survey for England 2014 1. A detailed description of the model is available in the 
online report 2.  
MiMiC-Bowel comprises natural history, symptomatic diagnosis, screening, and surveillance 
modules. In addition to age and sex, the model incorporates individual risk factors 3. Each person is 
assumed to have a normal colorectal epithelium at the age of 30. The population can move through 
nine health states reflecting the development of CRC (Figure 1). Precancerous conditions were 
classified as either low-risk adenomas (LRA) or high-risk adenomas (HRA) in line with the 
surveillance guidelines used in the UK from 2002 to 2019 4. CRC diagnosis may occur via 
symptomatic and chance diagnosis, or through screening. Diagnosis of pre-cancerous lesions in 
MiMiC-Bowel occurs only via screening. 
CRC development via serrated neoplastic pathways was represented in the model as transition from 
normal epithelium directly to CRC stage A 5. The transition probability from normal epithelium to 
CRC stage A was increasing linearly between ages 15 and 100 to reflect the absence of recorded cases 
for persons younger than 15 years 6. As no data identified differences in CRC stage distribution by 
sex, transitions between CRC stages and symptomatic presentation rates (except for persons on CRC 
stages A and B older than 75 years, to address the lower symptomatic presentation among older 
population 7) were assumed to be invariant by age and sex 8 9.  
2. Uncertainty of the MiMiC-Bowel predictions 
Because of the stochastic nature of the model, the predictions of the model on smaller populations 
may vary significantly for rare events, such as CRC cases in young persons. To determine the model 
population size required to ensure stable calibration results, the model was run for a range of 
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population sizes up to 6.7 million. Standard errors in modelling predictions of CRC incidence among 
males and females was generated for populations of different sizes (Figure 1). The maximum standard 
error of CRC incidence among modelled population of less than 0.1 (considered acceptable) was 
achieved with the population of 1.3 million people. 
Figure 1. Standard errors in modelling predictions of CRC incidence among males (1a) and 







3. Calibration of the MiMiC-Bowel: the framework 
To calibrate the MiMiC-Bowel model we developed the following framework based on a trial-and-
error approach:  
(1) Selection of the calibration targets and assessment of their compatibility; 
(2) Selection of the algorithm and acceptance metrics; 
(3) Calibrating the model using the step-wise approach combining a manual search to find an initial 
set of parameters and Metropolis–Hastings (MH) algorithm to retrieve the distribution of the 
parameters; 
(4) Validating the predictions against expected sensitivity values for screening tests. 
(5) Cross-validating the MiMiC-Bowel predictions to other models.  
4. Calibration targets of the MiMiC-Bowel 
4.1. Calibration targets 1&2: Prevalence of adenomas (unscreened 
population) 
Data on prevalence of adenomas in the UK were not available, so data from comparable settings were 
considered. Data on advanced/non-advanced lesions from the German colonoscopy screening 
programme were selected as the most reliable estimates due to the large sample sizes (> 4 million 
people) and geographical similarity compared to other studies 8 10. 
Prevalence of adenomas was estimated as the detection rate of pre-cancerous lesions at screening 
colonoscopy in a previously unscreened population divided by the estimated sensitivity of screening 
colonoscopy (0.765 for LRA and a 0.925 for HRA) 11 12. Further adjustments were made to German 
data to make it more comparable to the UK, using information from the UK Flexible Sigmoidoscopy 




Box 1. Adjustment of low and high risk adenoma data to reflect the prevalence of non-advanced 
and advanced adenoma 
The definition of advanced adenoma used by Brenner et al (2010)9 differed from the high risk/low risk 
categorisation used in MiMiC-Bowel. The UKFSS Trial 14 collected information on both advanced adenoma 
and HRA prevalence following flexible sigmoidoscopy (personal communication with the authors), and was 
used to convert the prevalence of advanced and non-advanced lesions reported by Brenner et al (2014) 8 to 
high- and LRA. The proportion of advanced adenomas that are high-risk was 0.81 for males and 0.66 for 
females. Using this conversion approach for adenoma prevalence based on Brenner colonoscopy screening 
assumes that these ratios are similar for proximal and distal CRC which may not be the case (unlike 
colonoscopy, flexible sigmoidoscopy has very low sensitivity to proximal CRC); however, other evidence 
was not available.  
The process of data conversion was the following: 
1. Prevalence of advanced and non-advanced adenoma was calculated from detection rate and test 
sensitivity (0.966 for advanced and 0.765 for non-advanced adenoma). 
2. Total adenoma prevalence was calculated as a sum of advanced and non-advanced adenoma. 
3. Prevalence of HRA was calculated by multiplying prevalence of advanced adenoma among men by 
0.81 and among women by 0.66. 
4. Prevalence of LRA was calculated as the difference between total adenoma prevalence and HRA 
prevalence.  
 
4.2. Calibration targets 3-7: Undiagnosed CRC prevalence total and by stages 
Undiagnosed CRC prevalence was defined as the number of persons with undiagnosed CRC in an 
unscreened population. The detection rate of CRC at screening colonoscopy by age and sex for the 
55-73 year-old population in the German national colonoscopy screening registry 2003 to 2007 was 
used 9. Undiagnosed CRC prevalence was estimated as CRC detection rate divided by colonoscopy 
sensitivity to CRC (0.966)15. Observing an approximately 10% higher incidence of CRC in Germany 
compared to England prior to screening implementation (Figure 2) and constrained by the absence of 
data on undiagnosed CRC in England, we adjusted the prevalence of undiagnosed cancer in Germany 
downwards to reflect this difference. Firstly, the German prevalence data9 were multiplied by 0.9 to 
represent the likely underlying prevalence in England. The data then were also adjusted to take 
account of model cycle length limitations arising from calculating the outcomes at the end of the 
annual model cycle in contrast to the target prevalence data that were sourced from colonoscopy 
screening study inviting the population through the year. This adjustment was required because it 
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would be expected that German colonoscopy screening would pick up some people who would 
normally be diagnosed symptomatically by the end of the year anyway, and on average, half of the 
people due to present symptomatically that year would be picked up by screening before symptomatic 
diagnosis. These people should already be counted in diagnosed incidence data for that year, and so 
should be excluded from the undiagnosed prevalence data. To do this, half of the annual CRC 
incidence in Germany in 2003-2004 was scaled to the target population size and then subtracted from 
CRC undiagnosed prevalence data in males and females. For the population of screening start age 
(55-59 years), this conversion due to undiagnosed prevalence required a multiplier of 0.88 for males 
and 0.85 for females.  
Figure 2. Comparison of CRC incidence in Germany and England  
 
Stage distribution of undiagnosed CRC was based on a German multi-centre cohort study in 2003-
2010 16. It was assumed that stages I-IV applied in Brenner et al (2016) 16 correspond to stages A to D 








































Germany, 2003-2006, male Germany, 2003-2006, female
England,  2005, male England,  2005, female
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Table 1. Undiagnosed CRC prevalence, target data used in model calibration 
Sex and Age Population Prevalence 
Total stage A stage B stage C stage D 
Male, 55-59 236028 1166 595 198 315 58 
Male, 60-64 272832 2045 1043 348 552 102 
Male, 65-69 281400 2778 1417 472 750 139 
Male, 70-75 170073 2506 1278 426 677 125 
Female, 55-59 351716 863 440 147 233 43 
Female, 60-64 354559 1293 659 220 349 65 
Female, 65-69 330965 1729 882 294 467 86 
Female, 70-75 187580 1528 779 260 413 76 
 
4.3. Calibration targets 8-12: Total CRC incidence, developed through 
serrated pathways, and by stages 
English data from 2005 Cancer Registration Statistics were used together with census data for 
England (2005) 6 17(Table 2, Figure 3) to assess CRC incidence in the absence of screening. For both 
males and females 15% of CRC cases were assumed to develop through the serrated neoplastic 
pathway 5 18.  



















30-34 45 2,087,828 2 0.002% 43 2,117,737 2 0.002%
35-39 107 2,305,591 5 0.005% 89 2,339,424 4 0.004%
40-44 196 2,284,554 9 0.009% 181 2,331,691 8 0.008%
45-49 404 2,011,847 20 0.020% 330 2,040,492 16 0.016%
50-54 681 1,820,534 37 0.037% 512 1,852,733 28 0.028%
55-59 1,387 1,936,082 72 0.072% 899 1,978,944 45 0.045%
60-64 1,715 1,528,329 112 0.112% 1,094 1,590,038 69 0.069%
65-69 2,285 1,302,570 175 0.175% 1,491 1,407,541 106 0.106%
70-74 2,802 1,079,412 260 0.260% 1,908 1,253,751 152 0.152%
75-79 2,936 835,292 351 0.351% 2,269 1,104,514 205 0.205%
80-84 2,241 559,108 401 0.401% 2,254 908,552 248 0.248%
85+ 1,426 343,698 415 0.415% 2,166 820,546 264 0.264%
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Figure 3. CRC incidence used in MiMiC-Bowel model calibration by sex  
 
To include CRC incidence by stage we used the data on stage distribution for the population aged 0 to 
100 diagnosed between 1996 and 2004 in England. A review of sex-related differences in CRC 
incidence in the UK suggested no clear difference by sex for stage I/II or for more advanced stages 19. 
The same stage distribution for CRC incidence was applied for males and females to obtain sex 
specific target data (Figure 4).  























































CRC incidence by stage, England 1996-2004
Males, CRC stage A
Males, CRC stage B
Males, CRC stage C
Males, CRC stage D
Females, CRC stage A
Females, CRC stage B
Females, CRC stage C
Females, CRC stage D
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4.4. Compatibility of calibration targets 
The data selection process considered multiple characteristics of the sources of calibration targets, 
including the quality of the reporting of the data and their representativeness to the general population 
of the country, population sample size, healthcare and population comparability. The compatibility of 
datasets used in the calibration process was explored through analysis of: 
(1) Incidence in the studied population (England) and the population for sourced data (Germany);  
(2) Consistency in the direction of change in calibrated parameters to fit each of the multiple 
databases separately; 
(3) Compatibility of the data used in the calibration (prevalence of lesions retrieved from German 
sources) against other data sources that were not directly used to calibrate the model (predicted faecal 
immunochemical test [FIT] test sensitivity in England). 
 
5. Algorithm and acceptance metrics 
5.1. Goodness-of-fit metric 
The calibration process aims to obtain a parameter set with a good fit to each of the calibration targets 
(12 for each sex). This is achieved by minimising the total sum of squared errors (SSE):  
 
  𝑇𝑜𝑡𝑎𝑙 𝑆𝑆𝐸 = ( ∑  𝑁 𝑜𝑓 𝑑𝑎𝑡𝑎 𝑝𝑜𝑖𝑛𝑡𝑠𝑖𝑤𝑒𝑖𝑔ℎ𝑡 𝑖 ×  𝑣𝑎𝑟𝑖𝑎𝑛𝑐𝑒𝑖 × 𝑆𝑆𝐸𝑖# 𝑑𝑎𝑡𝑎 𝑡𝑎𝑟𝑔𝑒𝑡𝑠𝑖=1 ) + ( ∑ 𝑝𝑟𝑖𝑜𝑟𝑗𝑤𝑒𝑖𝑔ℎ𝑡𝑗
# 𝑝𝑟𝑖𝑜𝑟𝑠
𝑗=1 ) 
Where i –the target data set by sex (eg CRC A incidence among females), SSEi – sum of squared 
errors for each data set i, N of data pointsi - number of age groups for which data were reported in the 
data set i, j – contribution of a weighted prior j to the total SSE, weighti and weightj  are weightings 
assigned to each target data set i and each prior j (a measure of how relevant the data are for the 




Table 3. Weightings, variances and priors used in the calibration 





1 LRA prevalence 0.5 5 42,280,670 26,101,070 
2 HRA prevalence 0.5 5 3,472,459 1,232,347 
3 Undiagnosed CRC  0.5 4 17,581 6,967 
4 Undiagnosed CRC A 0.5 4 4,574 1,812 
5 Undiagnosed CRC B 0.5 4 508 201 
6 Undiagnosed CRC C 0.5 4 1,282 508 
7 Undiagnosed CRC D 0.5 4 44 17 
8 CRC incidence 1 12 30,863 20,882 
9 CRC A incidence  0.5 12 176 99 
10 CRC B incidence  0.5 12 1,484 929 
11 CRC C incidence  0.5 12 4,901 3,301 
12 CRC D incidence  0.5 12 2,957 2,259 
13 CRC incidence developed through serrated 
pathways* 
1 1 236,926 157,673 
The priors Weight Mean, (95% CI) 𝑨𝒍𝒑𝒉𝒂, 𝑩𝒆𝒕𝒂, 𝒎𝑪** 
Males Females Males Females 






143.1, 595, 361.1 






Abbreviations: CRC - colorectal cancer, LR – low-risk, HR – high-risk. 
* The variance calculation for CRC incidence developed through serrated pathways was based on assumption of high 
uncertainty in the expected values, assumed being between 12% and 18%. 
 
** Calculation of the priors components (alpha, beta, and mC) was based on mean prevalence of lesions in age group 75-79 
years old and standard distribution assuming the prevalence in age group older than 80 years be within 15% of the 
prevalence in age group 75-59 years. The calculation of priors using Alpha, beta, and mC components was the following: 𝑇ℎ𝑒 𝑝𝑟𝑖𝑜𝑟 = −[(𝛼 − 1)𝑙𝑜𝑔(𝑝𝑟𝑒𝑣𝑎𝑙𝑒𝑛𝑐𝑒) + (𝛽 − 1)𝑙𝑜𝑔(1 − 𝑝𝑟𝑒𝑣𝑎𝑙𝑒𝑛𝑐𝑒) − 𝑚𝐶] 
 
The objective function component variancei was calculated as the SSE when comparing the target 
data to 3% error on target data. Hence, the variances scale the SSE’s for each data set relative to the 
number of observations in the data set: 
 𝑣𝑎𝑟𝑖𝑎𝑛𝑐𝑒𝑖 = ∑  (𝑂𝑐𝑐𝑢𝑟𝑟𝑒𝑛𝑐𝑒𝑛,𝑖 × 3%)2# 𝑎𝑔𝑒 𝑔𝑟𝑜𝑢𝑝𝑠𝑛=1  
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Where variancei - variance for the target data set i, occurrencen,i – number of occurrences in the target 
data set i in each age group n; n – age group for which occurrence is reported. 
 
This ensures that the objective function will result in a model which fits to all the data sets and avoids 
domination by the data set with the largest numbers. 
Data on the prevalence of LRA and HRA was not available for persons aged 80 and over with the 
model predicting more than 30% of prevalence events in persons aged 80 comparing to 75 years 
(what was considered as implausible). Thus, the calibration applied a prior that the prevalence in this 
age group would be within 15% of that observed for persons aged 75-79 years. The weightings, 
variances and calculation of contribution of the priors to total SSE are detailed in Table 3. 
5.2. Search strategy and acceptance criteria 
The calibration used the MH algorithm 20 (Figure 5) to estimate the posterior probability distributions 
of model parameters. An increment, epsilon (initially set at 10% of each parameter’s value), was used 
for each parameter to determine the maximum step size for each iteration of the algorithm. The new 
parameter set values are obtained by adding a random sample from a uniform distribution (-epsilon, 
epsilon) to the current parameter values. As the algorithm converges on the solution parameter set it is 
efficient to reduce the maximum step size. This tuning was achieved by using an epsilon multiplier, 
which was initially set to one and subsequently decreased by 20% if during the last 25 calibration 
cycles two or less parameter sets were accepted. 
The proposal parameter set in calibration was always accepted if the proposal parameter set had lower 
total SSE than the current parameter set (p = 1). The probability that the proposed parameter set was 
accepted when it results in higher SSE than with the current parameter set was:  
𝑝 =  𝑒(−0.5×(𝑇𝑜𝑡𝑎𝑙 𝑆𝑆𝐸(𝑝𝑟𝑜𝑝𝑜𝑠𝑒𝑑 𝑠𝑒𝑡) −𝑇𝑜𝑡𝑎𝑙 𝑆𝑆𝐸(𝑐𝑢𝑟𝑟𝑒𝑛𝑡 𝑠𝑒𝑡))) 
Where p – probability of accepting the proposal parameter if the SSE with proposed parameter set is 




Figure 5. Metropolis–Hastings algorithm to calibrate of model parameters 
 
The probability of accepting a proposal set which increases the objective function by more than 5 
units is less than 10%. 
5.3. Step-wise calibration approach 
As the model is complex (requiring calibration of 47 parameters) and computationally intensive to run 
(around 26 minutes for one calibration run, i.e. for population of 1.3 million people), an approach of 
fitting to all data sets simultaneously was found to be unfeasible. Hence a step-wise calibration 
approach (Table 4) was adopted in this project to enable fit to the multiple data sets by finding a good 
estimation for the initial set of calibration parameters. The way in which the calibration process was 
split into consequential steps was based on the nature of CRC development (Figure 6) and the 
modelling assumptions. Step one applied manual adjustment of the parameter to fit CRC incidence 
developed via serrated pathways since only one value required adjustment. The purpose of manual 
adjustment of parameters at step 2 was to retrieve a good starting parameter set to be used in MH-
algorithm (step 3), and so the retrieved values of the parameters were not fixed in the following 
calibration steps.  Steps one, three, four, and five resulted in fixing different sets of calibrated 
parameters to their final values. Step 6 used the final parameter values retrieved from the previous 
steps (i.e. used a starting parameter set with good fit to all target databases) to retrieve the 















Table 4. Step-wise calibration process of MiMiC-Bowel 
Step Parameters calibrated Target data set(s)1 Approach  N of 
parameters  
1 Transition from normal epithelium to 
CRC A 
CRC incidence via serrated 
pathway 
Manual2 1 
2 NHD parameters Adenoma prevalence, CRC 
incidence 
Manual2 43 
3 Pre-cancer NHD parameters for males Adenomas prevalence, CRC 
incidence, and undiagnosed 
CRC (males) 
MH-algorithm 18 
4 Cancer NHD parameters (transitions 
between cancer stages, symptomatic 
presentation rate, probability of death 
from undiagnosed CRC D, decrement 
of symptomatic presentation among 
people older than 75 years old) 
CRC incidence, undiagnosed 
CRC and CRC by stages 
(males) 
MH-algorithm 9 
5 Pre-cancer NHD parameters for 
females 
Adenoma prevalence, CRC 
incidence, and undiagnosed 
CRC (females) 
MH-algorithm 18 
6 All NHD parameters: pre-cancer and 
cancer NHD parameters, symptomatic 
presentation rates, probability of death 
from undiagnosed CRC D, decrement 
of symptomatic presentation among 
people older than 75 years old 
All calibration targets: 
Adenomas prevalence, CRC 
incidence, undiagnosed CRC, 
incidence and undiagnosed CRC 
by stages (males and females) 
MH-algorithm 47 
1 See sub-sections on calibration targets explaining how they were derived 
2 Manually adjusting the parameters to fit calibration targets  




Figure 6. Structure of the CRC natural history model health states and calibration steps 
 
6. Calibration outcomes  
6.1. CRC natural history model parameter estimates obtained via calibration  
The applied calibration framework allowed retrieval of the model parameters (Table 5 and Figure 7). 
Transition probabilities differed by sex being higher for males transitioning from normal epithelium to 
LRA and LRA to HRA up to age 63 while being higher for females of all ages transitioning from 
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CRC Duke Stage B 
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Mean Posterior Estimate (95% 
Credible Interval Percentiles) 
Transition probability from normal epithelium to LRA, male, 37 y.o 0.0020 0.00196 ( 0.00196, 0.00197) 
Transition probability from normal epithelium to LRA, male, 47 y.o. 0.0268 0.02714 ( 0.02711, 0.02717) 
Transition probability from normal epithelium to LRA, male, 57 y.o. 0.0149 0.01498 ( 0.01497, 0.01500) 
Transition probability from normal epithelium to LRA, male, 67 y.o. 0.0082 0.00808 (0.00807, 0.00809) 
Transition probability from normal epithelium to LRA, male, 77 y.o. 0.0044 0.00432 ( 0.00431, 0.00433) 
Transition probability from normal epithelium to LRA, male, 87 y.o. 0.0032 0.00324 ( 0.00323, 0.00324) 
Transition probability from LRA to HRA, male, 37 y.o. 0.0282 0.02818 ( 0.02815, 0.02821) 
Transition probability from LRA to HRA, male, 47 y.o. 0.0313 0.03184 ( 0.03180, 0.03188) 
Transition probability from LRA to HRA, male, 57 y.o. 0.0206 0.02069 ( 0.02067, 0.02072) 
Transition probability from LRA to HRA, male, 67 y.o. 0.0121 0.01224 ( 0.01222, 0.01226) 
Transition probability from LRA to HRA, male, 77 y.o. 0.0155 0.01515 ( 0.01511, 0.01518) 
Transition probability from LRA to HRA, male, 87 y.o. 0.0093 0.00924 ( 0.00923, 0.00925) 
Transition probability from HRA to CRC, male, 37 y.o. 0.0092 0.00916 ( 0.00915, 0.00918) 
Transition probability from HRA to CRC, male, 47 y.o. 0.0163 0.01618( 0.01616, 0.01620) 
Transition probability from HRA to CRC, male, 57 y.o. 0.0181 0.01739 ( 0.01737, 0.01741) 
Transition probability from HRA to CRC, male, 67 y.o. 0.0284 0.02759 ( 0.02752, 0.02765) 
Transition probability from HRA to CRC, male, 77 y.o. 0.0502 0.05120 ( 0.05112, 0.05128) 
Transition probability from HRA to CRC, male, 87 y.o. 0.0352 0.03584 ( 0.03580, 0.03588) 
Transition probability from normal epithelium to LRA, female, 37 y.o. 0.0012 0.00115 ( 0.00115, 0.00115) 
Transition probability from normal epithelium to LRA, female, 47 y.o. 0.0162 0.01638 ( 0.01636, 0.01640) 
Transition probability from normal epithelium to LRA, female, 57 y.o. 0.0115 0.01145 ( 0.01144, 0.01147) 
Transition probability from normal epithelium to LRA, female, 67 y.o. 0.0083 0.00845 ( 0.00843, 0.00846) 
Transition probability from normal epithelium to LRA, female, 77 y.o. 0.0040 0.00389 ( 0.00388, 0.00389) 
Transition probability from normal epithelium to LRA, female, 87 y.o. 0.0030 0.00307 ( 0.00307, 0.00307) 
Transition probability from LRA to HRA, female, 37 y.o. 0.0175 0.01831 ( 0.01827, 0.01834) 
Transition probability from LRA to HRA, female, 47 y.o. 0.0285 0.02838 ( 0.02834, 0.02841) 
Transition probability from LRA to HRA, female, 57 y.o. 0.0145 0.01427( 0.01425, 0.01428) 
Transition probability from LRA to HRA, female, 67 y.o. 0.0144 0.01416( 0.01414, 0.01418) 
Transition probability from LRA to HRA, female, 77 y.o. 0.0199 0.01937( 0.01935, 0.01940) 
Transition probability from LRA to HRA, female, 87 y.o. 0.0114 0.01179 ( 0.01177, 0.01181) 
Transition probability from HRA to CRC, female, 37 y.o. 0.0047 0.00477 ( 0.00477, 0.00478) 
Transition probability from HRA to CRC, female, 47 y.o. 0.0208 0.02032( 0.02029, 0.02035) 
Transition probability from HRA to CRC, female, 57 y.o. 0.0272 0.02673 ( 0.02669, 0.02676) 
Transition probability from HRA to CRC, female, 67 y.o. 0.0359 0.03647 ( 0.03642, 0.03653) 
Transition probability from HRA to CRC, female, 77 y.o. 0.0650 0.06384 ( 0.06371, 0.06398) 
Transition probability from HRA to CRC, female, 87 y.o. 0.0531 0.05283( 0.05276, 0.05289) 
Transition probability from normal epithelium to CRC at age 100  
(linear gradient with the transition set to zero at age 15) 
0.0006 0.00056 ( 0.00056, 0.00056) 
Decrement in symptomatic cancer A,B presentation among people older than 75 years 0.0361 0.03715 (0.037103, 0.03720) 
Probability to die undiagnosed at stage D 0.0400 0.04029 (0.04026, 0.04032) 
Transition probability from CRC stage A to stage B 0.2932 0.28784 ( 0.28745, 0.28822) 
Transition probability from CRC stage B to stage C 0.5539 0.56207 ( 0.56104, 0.56310) 
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Transition probability from CRC stage C to stage D 0.3500 0.36705 ( 0.36655, 0.36756) 
Probability of being symptomatic, CRC stage A 0.0203 0.02025 ( 0.02022, 0.02029) 
Probability of being symptomatic, CRC stage B 0.1429 0.12981 ( 0.12965, 0.12996) 
Probability of being symptomatic, CRC stage C 0.2741 0.26771 ( 0.26738, 0.26804) 
Probability of being symptomatic among those who die diagnosed, CRC stage D 0.2500 0.20386 ( 0.20359, 0.20413) 
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Figure 7a
Transition probability from normal epithelium to low-risk adenoma, male
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Figure 7b
Transition probability from low-risk adenoma to high-risk adenoma, male
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Figure 7c
Transition probability from high-risk adenoma to colorectal cancer, female
Transition probability from high-risk adenoma to colorectal cancer, male
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6.2. Fit of the model to target data sets  
The model parameters derived via the calibration process resulted in a good fit between model 
outcomes and target prevalence of adenomas, CRC incidence, undiagnosed CRC, and CRC incidence 
by stages (Figure 8). For incidence of CRC, model predictions were within target data confidence 
intervals for women of all ages except 75-85 year olds (0.7-6.6% difference in the means), and for 
men from 45 to 80 years old. The prevalence of HRA, which precedes CRC development, was within 
confidence intervals for all females and males.  
Figure 8. Predicted modelling and target outcomes 
  
Figure 8a. Prevalence of LRA predicted by the model to target data  
 



































LRA prevalence – male, MiMiC model predictions







































HRA prevalence – male, MiMiC model predictions




Figure 8c. Prevalence of CRC predicted by the model to target data  
 


































CRC prevalence – male, MiMiC model predictions
CRC prevalence – female, MiMiC model predictions






































CRC incidence – male, MiMiC model predictions
CRC incidence – female, MiMiC model predictions




Figure 8e. Incidence of CRC among males predicted by the model to target data  
 







































CRC A incidence – male, MiMiC model predictions CRC B incidence – male, MiMiC model predictions
CRC incidence male – calibration target CRC C incidence – male, MiMiC model predictions





































CRC A incidence – female, MiMiC model predictions CRC B incidence – female, MiMiC model predictions
CRC C incidence – female, MiMiC model predictions CRC D incidence – female, MiMiC model predictions
CRC incidence female – calibration target
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6. Validation of MiMiC-Bowel 
The validation of MiMiC-Bowel included comparisons of the following predictions: (a) sensitivity of 
screening tests (flexible sigmoidoscopy [FS] and FIT20) to plausible sensitivity values (external 
validity of the model); (b) unobserved outcomes (e.g. time of tumour progression) to predictions from 
Cancer Intervention and Surveillance Modeling Network (CISNET) models 21 22; and (c) risks of 
lesions to estimations in a German model by Brenner et al (2014) 8.  
6.1. External validity of screening sensitivity estimated using MiMiC-bowel 
For FIT20, validation assumed upper bound of sensitivity to CRC of 60% 23.  The process of 
calculation of upper bounds of sensitivity rates of FS in population aged 55 years is reported in Box 2; 
this resulted to the upper bound for sensitivity of FS in population screening was 72% for CRC and 
69% for HRA. 
Box 2. Steps for calculation of sensitivity of FS used as upper bounds in validation 
1. Sensitivity of FS was retrieved from the literature:12 24 in distal colon – 97% for CRC and 93% for 
advanced adenoma, and in proximal colon – 21% for both CRC and advanced adenoma. 
2. Proportion of proximal and distal lesions in population aged 55 years diagnosed with CRC was 
assessed from UKFSST data:25 distal colon/rectum represents 79% of lesions in males and 71% in 
females. 
3. Sensitivity of FS to CRC and advanced adenoma was calculated by weighting to the proportions of 
proximal and distal lesions: sensitivity to proximal lesions* proportion of proximal lesions + 
sensitivity to distal lesions *proportion of distal lesions. This resulted in an estimate of the upper 
bound of sensitivity in the trial (UKFSST) of 78% for CRC and 75% for HRA. 
4. The predicted sensitivity of FS in UKFSST was adjusted to a ratio of lesions detection rate in the 
national bowel cancer screening programme (BCSP) and UKFSST.  The comparative performance 
of BCSP and UKFSST was calculated using the detection rates of CRC (0.17% in BCSP and 0.24% 
in UKFSST) and the detection rates of HRA (2.20% in BCSP and 2.32% in UKFSST). The division 
of detection rate of lesions in BCSP (2.37%) and the detection rate of lesions in UKFSST (2.56%), 




Sensitivity of tests was calculated by dividing detection rates in BCSP (Box 2) and FIT pilot by 
prevalence of lesions estimated with the target calibration datasets. 
Using the BCSP in England as a target, the calibrated model predicted the sensitivity of FS at 60% for 
CRC and 59% for HRA for 55-year olds, what is below the calculated upper bound values. The 
predicted sensitivity of FIT20 for population aged 55 years was 48% for CRC and 32% for HRA, 
what is also below the upper bound values reported in the literature.  
6.1. Cross-validity of MiMiC- Bowel model to CISNET models 
The first part of the cross-validation was conducted through comparison of the CRC disease natural 
histories between three models of the CISNET 21 22. Since no confidence interval was reported for the 
CISNET model predictions, cross-validation assumed fitting the confidence interval or outcomes 
generated by MiMiC-Bowel to ranges reported by three CISNET models. Considering lack of 
information whether cross-validation of CISNET models considered all adenomas as detectable (or 
only HRA), 21 22  the validation task retrieved predictions of MiMiC-Bowel on all- and high-risk 
adenomas separately. 
Unlike the CISNET models, MiMiC-Bowel predicted considerably slower growth of adenomas 
among older populations (Table 6). If all adenomas are considered to be detectable, then the predicted 
values of the proportion of adenomas developed within 10- and 20-years of CRC diagnosis in 
CISNET models were generally higher than values predicted by MiMiC-Bowel. If only HRA are 
considered 100% detectable, MiMiC-Bowel predictions were slightly higher than those of CRC-SPIN 
and SimCRC models, though still lower than the predictions of the MISCAN model 22.  
Table 6. CRC cases that arise from potentially detectable adenomas: model predictions for MiMiC-
Bowel and CISNET models21 22 
Age at CRC 
diagnosis 




Adenomas developed within 10 years of CRC diagnosis (%) 
55 72 3 10 18 48 
25 
 
65 67 4 9 3 28 
75 62 4 9 1 23 
Percent of adenomas developed within 20 years of cancer diagnosis (%) 
65 94 24 39 47 77 
75 92 25 37 16 59 
85 89 28 33 8 53 
 *The 95% confidence interval is narrower than 0.1 unit point and so is not reported here 
For the percentage of adenomas developing into CRC over time, MiMiC-Bowel predictions around 
sojourn and dwell time were closer to CRC-SPIN and SimCRC models than to MISCAN 22 (Table 7); 
both dwell time and sojourn time were however, higher in MiMiC-Bowel. The CISNET models 
predicted the cumulative 20-year incidence rate for a 55-year old cohort under a condition of no other 
cause mortality among the US population (3.2-3.6%), which was higher than those predicted by 
MiMiC-Bowel in England (Table 8): 2.62%, 95%CI (2.61-2.63) among males and 1.55%, 95%CI 
(1.50-1.51) among females with the 2005 population cohort. MiMiC-Bowel predicted the 20-year 
incidence as almost 10-fold higher among persons with adenomas than with normal epithelium at age 




Table 7. Model predicted sojourn and dwell time for MiMiC-Bowel and CISNET models21 22 
Summary measure MISCAN  CRC-
SPIN  








Adenoma dwell time (from LRA incidence 
to CRC A) 
7.6 24.2 21.2 29.1 29.1 
Sojourn time (from preclinical CRC A to 
CRC diagnosis)  
3.0 1.6 4.0 5.3 5.4 
Overall dwell time (from LRA to CRC 
diagnosis) 
10.6 25.8 25.2 34.4 34.5 
CRC – colorectal cancer; LRA – low-risk adenoma 
*The 95% confidence interval is narrower than 0.1 unit point and so is not reported here 
Table 8. Cumulative colorectal cancer incidence for 55-year-old cohort 
Predicted outcomes CISNET models, 
range22 
MiMiC -Bowel model 
Persons Males Females 
20-year cancer 





(5.1% for those with 
adenoma at 55, 0.6% 




(6% for males 
with adenoma at 
55, 0.7% with 
NE at age 55) 
1.5% 
 
(4.2% for females 
with adenoma at age 
55, 0.5% with NE at 
age 55) 
20-year cancer 
incidence for 55- year 
old cohort with 
polypectomy at age 55 
years 
 










incidence for the whole 
cohort of 55 year olds  
Not reported 0.7%  0.8%  0.6%  
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65%  71% 60% 
CRC – colorectal cancer, NE – normal epithelium, y.o – year-old 
 
Predictions of 20-year CRC incidence for a 55-year-old cohort with perfect polypectomy at age 55 
years, resulted in decreased incidence compared to CISNET models: 0.9%, 95%CI (0.91 – 0.93) in 
MiMiC-Bowel vs 0.4-2.7%. This reduced 20- year incidence in the whole population (including those 
who had normal epithelium anyway) to 0.7% (0.6% in females and 0.8% in males). The perfect 
polypectomy resulted in a 71% reduction in 20-y cumulative cancer risk in MiMiC-Bowel, - within 
the range 30-89% predicted by CISNET models 22. The ratio of 20-year CRC risks for people with 
lesions at 55 and for people with normal epithelium at 55 years was comparable to the MISCAN 
model (8.5 in MIMIC-bowel vs 7 in MISCAN), while it was much higher in the other two CISNET 
models (29 in SimCRC and 75 in CRC-SPIN)22, which could be related to definition of detectable 
lesions (all lesions vs only HRA). Perfect polypectomy decreased the ratio of the 20-year CRC risks 
to 1.33 in MiMiC-Bowel. A ratio higher than 1 is expected given that MiMiC-Bowel is based on 
individual level risks and people who develop adenomas by age 55 years will tend to be higher risk 
and so more likely to develop CRC in the future than people who did not develop adenomas by age 55 
years. 
6.2. Cross-validity of MiMiC- Bowel to modelled predictions in Germany  
The second part of cross validation included comparing risks of lesions (adenoma, clinically manifest 
CRC, all CRC cases) up to various ages for men and women free of neoplasm at screening 
colonoscopy by age, estimated in a German model by Brenner et al (2014) assuming 100% sensitivity 
for colonoscopy 8. The prevalence of HRA predicted by MiMiC-Bowel was converted to advanced 
adenoma rate 13.  
For both men and women, MiMiC-Bowel predicted slightly higher risk of CRC incidence among 
those with negative colonoscopy at defined age than reported by Brenner et al (2014) 8; this risk 
though increased with time less rapidly in MiMiC-Bowel than in the German model, resulting in 
28 
 
higher predictions at age 80 years in Germany than England, for each age (55-70 year old) at negative 
colonoscopy (Table 9).  
Table 9. Risk of clinically manifest CRC up to various ages for men and women free of neoplasm at 






Risk of clinically manifest CRC (%) up to 
age (years) 
Women 
Risk of clinically manifest CRC (%) up to 
age (years) 
65 70 75 80 65 70 75 80 
Brenner et al (2014) 8 
55 0.09 0.44 1.26 2.48 0.04 0.25 0.82 1.86 
60  0.09 0.49 1.26  0.06 0.34 1.03 
65   0.11 0.51   0.09 0.44 
70    0.10    0.10 
MiMiC-Bowel (predictions with the best-fit parameters) 
55 0.18  0.39  0.68  1.0  0.16  0.34  0.60  1.0  
60  0.19  0.38  0.61   0.16  0.35  0.64  
65   0.20  0.37    0.18  0.38  
70    0.19     0.19  






























 0.17* 0.34* 0.60 
(0.59-
0.61) 














70    0.19 
(0.18-
0.19) 
   0.18* 
CRC – colorectal cancer 
*The 95% confidence interval is narrower than 0.01 unit point and so is not reported here 
The 10-year risk of all CRC neoplasms and the risk of advanced neoplasms for men and women free 
of neoplasm at screening colonoscopy (and not undergoing any further CRC screening) was higher in 
all age groups in the German modelled population. Both cancer prevalence and incidence though were 
higher in MiMiC-Bowel (Table 10), which shows that in MiMiC-Bowel for a population aged 55 
years and older pre-cancer transitions were lower, while adenoma to CRC transitions were higher than 
in the German model. These differences may be explained by model structures: Brenner’s Markov 
model utilises a simpler five-state structure excluding serrated pathways 8. 




















Brenner et al (2014) model [8] 
55 20.4 3.4 0.28 0.09 13.3 2 0.14 0.04 
60 19.9 3.2 0.31 0.09 14 2.1 0.2 0.06 
65 19.1 3.2 0.4 0.11 14.2 2.6 0.3 0.09 
70 16 2.5 0.33 0.1 12.3 2.1 0.31 0.1 
MiMiC – Bowel model (predictions with the best-fit parameters) 
55 11.3 1.81 0.39 0.18 8.4 0.82 0.32 0.16 
60 8.4 1.10 0.38 0.19 6.2 0.71 0.35 0.17 
65 6.1 0.80 0.38 0.2 5.1 0.55 0.39 0.18 
70 4.3 0.59 0.35 0.19 3.7 0.39 0.39 0.19 
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MiMiC – Bowel model (mean and 95% confidence interval) 
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